Advances in treating chronic lymphocytic leukemia

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Tausch, Eugen ^a   Mertens, Daniel ^a,b   Stilgenbauer, Stephan ^a  

^a UNIVERSITY OF ULM   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTILEUKEMIC AGENT; B LYMPHOCYTE RECEPTOR; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; IBRUTINIB; IDELALISIB; LENALIDOMIDE; OBINUTUZUMAB; OFATUMUMAB; RITUXIMAB;

ALLOTRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B CELL LYMPHOMA; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; HEALTH CARE QUALITY; HUMAN; INFUSION RELATED REACTION; MINIMAL RESIDUAL DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PATIENT CARE; PROTEIN TARGETING; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME;

EID: 84906974615     PISSN: 20517599     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-65     Document Type: Article

References (54)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P: Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia. N Engl J Med 2000, 343:1910-6.
3. Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S: TP53 Mutation and Survival in Chronic Lymphocytic Leukemia. J Clin Oncol 2010, 28:4473-9.
4. Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S, Else M, Matutes E, Catovsky D; Chronic Lymphocytic Leukaemia Working Group, UK National Cancer Research Institute: Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 2010, 95:1705-12.
5. Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, Fink AM, Bühler A, Zenz T, Wenger MK, Mendila M, Wendtner C-M, Eichhorst BF, Döhner H, Hallek MJ, Kneba M: Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012, 30:980-8.
6. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-56.
7. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jäger U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Döhner H, Brittinger G, Emmerich B, Hallek M: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006, 107:885-91.
8. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJS, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P; UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group, NCRI Chronic Lymphocytic Leukaemia Working Group: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007, 370:230-9.
9. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H: Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia. J Clin Oncol 2005, 23:4079-88.
10. Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, Pflüger KH, Schott S, Goede V, Isfort S, von Tresckow J, Fink A-M, Bühler A, Winkler D, Kreuzer K-A, Staib P, Ritgen M, Kneba M, Döhner H, Eichhorst BF, Hallek M, Stilgenbauer S, Wendtner C-M: Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012, 30:3209-16.
11. thAnnual Meeting and Exposition of the American Society of Hematology: 7-10 December2013; New Orleans, LA.
12. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy M-S, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer K-A, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014, 370:1101-10.
13. thAnnual Meeting and Exposition of the American Society of Hematology: 7-10 December 2013; New Orleans, LA.
14. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, et al.: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164-74.
15. Maloney DG, Smith B, Rose A: Rituximab: mechanism of action and resistance. Semin Oncol 2002, 29(Suppl 2):2-9.
16. Meerten T van, Rijn RS van, Hol S, Hagenbeek A, Ebeling SB: Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity. Clin Cancer Res 2006, 12:4027-35.
17. Janas E, Priest R, Wilde JI, White JH, Malhotra R: Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 2005, 139:439-46.
18. Castillo J, Milani C, Mendez-Allwood D: Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Investig Drugs 2009, 18:491-500.
19. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJS, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Österborg A: Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 2010, 28:1749-55.
20. Wierda WG, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Gorczyca M, Chang C-N, Chan G, Gupta I, Nielsen TG, Russell CA; 407 Study Investigators: Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011, 117:6450-8.
21. thAnnual Meeting and Exposition of the American Society of Hematology: 7-10 December 2013; New Orleans, LA.
22. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CHT, Tutt A, Beers SA, Glennie MJ, Cragg MS, Illidge TM: Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011, 117:4519-29.
23. stAnnual Meeting and Exposition of the American Society of Hematology: 5-8 December 2009; New Orleans, LA.
24. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ: Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003, 101:3413-5.
25. Keating MJ, Flinn I, Jain V, Binet J-L, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99:3554-61.
26. Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H; German Chronic Lymphocytic Leukemia Study Group: Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009, 27:3994-4001.
27. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995, 85:1580-9.
28. Schnaiter A, Paschka P, Rossi M, Zenz T, Bühler A, Winkler D, Cazzola M, Döhner K, Edelmann J, Mertens D, Kless S, Mack S, Busch R, Hallek M, Döhner H, Stilgenbauer S: NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood 2013, 122:1266-70.
29. Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, Moran M, Lucas M, Lin T, Hackbarth ML, Proffitt JH, Lucas D, Grever MR, Byrd JC: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004, 103:3278-81.
30. Hillmen P, Skotnicki A, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C, Mayer J: Alemtuzumab compared with Chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25:5616-23.
31. Ramsay AG, Clear AJ, Fatah R, Gribben JG: Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012, 120:1412-21.
32. Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, MacDougall F, Lister TA, Lee AM, Calaminici M, Gribben JG: Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009, 114:4713-20.
33. Sharma RA, Steward WP, Daines CA, Knight RD, O'Byrne KJ, Dalgleish AG: Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer Oxf Engl 1990 2006, 42:2318-25.
34. Christian MS, Laskin OL, Sharper V, Hoberman A, Stirling DI, Latriano L: Evaluation of the developmental toxicity of lenalidomide in rabbits. Birth Defects Res B Dev Reprod Toxicol 2007, 80:188-207.
35. Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS: Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study. J Clin Oncol 2006, 24:5343-9.
36. Ferrajoli A, Lee B-N, Schlette EJ, O' Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111:5291-7.
37. Badoux XC, Keating MJ, Wen S, Wierda WG, O'Brien SM, Faderl S, Sargent R, Burger JA, Ferrajoli A: Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 2013, 31:584-91.
38. Bergmann MA, Goebeler ME, Herold M, Emmerich B, Wilhelm M, Ruelfs C, Boening L, Hallek MJ; German CLL Study Group: Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005, 90:1357-64.
39. Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA, Wang D-S, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen C-S, Byrd JC: Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008, 26:2519-25.
40. Wiestner A: Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies. J Clin Oncol 2013, 31:128-30.
41. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S: Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 2013, 369:32-42.
42. thAnnual Meeting and Exposition of the American Society of Hematology: 8-11 December 2012; Atlanta, GA.
43. Woyach JA, Furman RR, Liu TM, Oze HG, Zapatka M, Rupper AS, Xue L, Li D, Steggerda SM, Versele MD, Sandeeo S, Zhang J, Yilmaz AS, Jaglowski S, Blum KA, Lozanski A, Lozanski GJ, Danelle F, Barrientos J, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson A, Byrd JC: Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib. N Engl J Med 2014, 370:2286-94.
44. Chang BY, Francesco M, De Rooij MFM, Magadala P, Steggerda SM, Huang MM, Kuil A, Herman SEM, Chang S, Pals ST, Wilson W, Wiestner A, Spaargaren M, Buggy JJ, Elias L: Egress of CD19(+) CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 2013, 122:2412-24.
45. O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC: Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014, 15:48-58.
46. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG: The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008, 111:846-55.
47. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA: The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011, 118:3603-12.
48. thAnnual Meeting of the American Society of Clinical Oncology: 31 May-4 June 2013; Chicago, IL.
49. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM: Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 2014, 370:997-1007.
50. Jeff Porter Sharman, Steven E. Coutre, Richard R. Furman, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline Claudia Barrientos, Andrew David Zelenetz, Thomas J. Kipps, Ian Flinn, Paolo Ghia, Michael J. Hallek, Bertrand Coiffier, Susan Mary O'Brien, Eugen Tausch, Karl A. Kreuzer, Wendy Jiang, Thomas Michael Jahn, Mirella Lazarov, Stephan Stilgenbauer: Efficacy Of Idelalisib In Cll Subpopulations Harboring Del(17p) And Other Adverse Prognostic Factors: Results From A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial [abstract]. Presented at 2014 ASCO Annual Meeting: 30 May-3 June 2014; Chicago, IL.
51. Reed JC: Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997, 34(Suppl 5):9-19.
52. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DCS, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park C-M, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, et al.: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013, 19:202-8.
53. thAnnual Meeting and Exposition of the American Society of Hematology: 7-10 December 2013; New Orleans, LA.
54. thAnnual Meeting and Exposition of the American Society of Hematology: 7-10 December 2013; New Orleans, LA.